FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991336487> ?p ?o ?g. }

• W1991336487 endingPage "384" @default.
• W1991336487 startingPage "379" @default.
• W1991336487 abstract "<h3>Abstract</h3> <b>Objective</b> : To compare the feasibility of treatment, safety, and toxicity of intravenous amphotericin B deoxycholate prepared in either glucose or intralipid for empirical antimycotic treatment of neutropenic cancer patients. <b>Design</b> : Single centre stratified, randomised non-blinded phase II study. <b>Setting</b> : University hospital providing tertiary clinical care. <b>Subjects</b> : 51 neutropenic patients (leukaemia (35), lymphoma (11), solid tumours (5)) with refractory fever of unknown origin (24) or pneumonia (27). <b>Interventions</b> : Amphotericin B 0.75 mg/kg/day in 250 ml glucose 5% solution or mixed with 250 ml intralipid 20%, given on eight consecutive days then alternate days, as a 1-4 hour infusion. <b>Main outcome measures</b> : Feasibility of treatment, subjective tolerance (questionnaire), and objective toxicity (common toxicity criteria of the National Cancer Institute). <b>Results</b> : Study arms were balanced for age, sex, underlying malignancy, renal and liver function, and pre- and concomitant treatment with antibiotics and nephrotoxic agents. No statistically significant or clinically relevant differences were found between the treatment groups for: daily or cumulative dose and duration of treatment with amphotericin B; incidence and time of dose modifications or infusion duration changes related to toxicity; dose or duration of symptomatic support with opiates, antipyretics, or antihistamines; renal function; subjective tolerance; most common toxicity scores; course of infection; and incidence of treatment failures. Patients treated with amphotericin B in intralipid were given fewer diuretics (P<0.05) and therefore had more peripheral oedema (P<0.01) and needed less potassium supplementation (P<0.05) than patients given amphotericin in glucose. Acute respiratory events were more common in the intralipid arm (P<0.05). <b>Conclusions</b> : Amphotericin B 0.75 mg/kg/day in intralipid given on eight consecutive days then alternate days provides no benefit and is associated with potential pulmonary side effects possibly because of fat overload or an incompatibility of the two drugs." @default.
• W1991336487 created "2016-06-24" @default.
• W1991336487 creator A5005594026 @default.
• W1991336487 creator A5013231760 @default.
• W1991336487 creator A5016445594 @default.
• W1991336487 creator A5021550191 @default.
• W1991336487 creator A5022817254 @default.
• W1991336487 creator A5050691901 @default.
• W1991336487 creator A5070851905 @default.
• W1991336487 creator A5088828968 @default.
• W1991336487 date "1998-08-08" @default.
• W1991336487 modified "2023-10-14" @default.
• W1991336487 title "Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study" @default.
• W1991336487 cites W1899836010 @default.
• W1991336487 cites W1968475599 @default.
• W1991336487 cites W1972241996 @default.
• W1991336487 cites W1984509860 @default.
• W1991336487 cites W1985927278 @default.
• W1991336487 cites W1993981002 @default.
• W1991336487 cites W1996912022 @default.
• W1991336487 cites W2024659661 @default.
• W1991336487 cites W2035960777 @default.
• W1991336487 cites W2052707704 @default.
• W1991336487 cites W2066905247 @default.
• W1991336487 cites W2069872001 @default.
• W1991336487 cites W2109170829 @default.
• W1991336487 cites W2118095080 @default.
• W1991336487 cites W2124891047 @default.
• W1991336487 cites W2330655172 @default.
• W1991336487 cites W2338280344 @default.
• W1991336487 cites W2402051390 @default.
• W1991336487 cites W2411942853 @default.
• W1991336487 cites W2466010921 @default.
• W1991336487 cites W84273483 @default.
• W1991336487 doi "https://doi.org/10.1136/bmj.317.7155.379" @default.
• W1991336487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/28631" @default.
• W1991336487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9694753" @default.
• W1991336487 hasPublicationYear "1998" @default.
• W1991336487 type Work @default.
• W1991336487 sameAs 1991336487 @default.
• W1991336487 citedByCount "65" @default.
• W1991336487 countsByYear W19913364872012 @default.
• W1991336487 countsByYear W19913364872013 @default.
• W1991336487 countsByYear W19913364872014 @default.
• W1991336487 countsByYear W19913364872016 @default.
• W1991336487 countsByYear W19913364872017 @default.
• W1991336487 countsByYear W19913364872020 @default.
• W1991336487 crossrefType "journal-article" @default.
• W1991336487 hasAuthorship W1991336487A5005594026 @default.
• W1991336487 hasAuthorship W1991336487A5013231760 @default.
• W1991336487 hasAuthorship W1991336487A5016445594 @default.
• W1991336487 hasAuthorship W1991336487A5021550191 @default.
• W1991336487 hasAuthorship W1991336487A5022817254 @default.
• W1991336487 hasAuthorship W1991336487A5050691901 @default.
• W1991336487 hasAuthorship W1991336487A5070851905 @default.
• W1991336487 hasAuthorship W1991336487A5088828968 @default.
• W1991336487 hasBestOaLocation W19913364871 @default.
• W1991336487 hasConcept C120665830 @default.
• W1991336487 hasConcept C121332964 @default.
• W1991336487 hasConcept C126189478 @default.
• W1991336487 hasConcept C126322002 @default.
• W1991336487 hasConcept C141071460 @default.
• W1991336487 hasConcept C16005928 @default.
• W1991336487 hasConcept C2777063308 @default.
• W1991336487 hasConcept C2778850193 @default.
• W1991336487 hasConcept C2779548794 @default.
• W1991336487 hasConcept C2779629538 @default.
• W1991336487 hasConcept C2780402444 @default.
• W1991336487 hasConcept C2909039274 @default.
• W1991336487 hasConcept C29730261 @default.
• W1991336487 hasConcept C61511704 @default.
• W1991336487 hasConcept C71924100 @default.
• W1991336487 hasConcept C90924648 @default.
• W1991336487 hasConceptScore W1991336487C120665830 @default.
• W1991336487 hasConceptScore W1991336487C121332964 @default.
• W1991336487 hasConceptScore W1991336487C126189478 @default.
• W1991336487 hasConceptScore W1991336487C126322002 @default.
• W1991336487 hasConceptScore W1991336487C141071460 @default.
• W1991336487 hasConceptScore W1991336487C16005928 @default.
• W1991336487 hasConceptScore W1991336487C2777063308 @default.
• W1991336487 hasConceptScore W1991336487C2778850193 @default.
• W1991336487 hasConceptScore W1991336487C2779548794 @default.
• W1991336487 hasConceptScore W1991336487C2779629538 @default.
• W1991336487 hasConceptScore W1991336487C2780402444 @default.
• W1991336487 hasConceptScore W1991336487C2909039274 @default.
• W1991336487 hasConceptScore W1991336487C29730261 @default.
• W1991336487 hasConceptScore W1991336487C61511704 @default.
• W1991336487 hasConceptScore W1991336487C71924100 @default.
• W1991336487 hasConceptScore W1991336487C90924648 @default.
• W1991336487 hasIssue "7155" @default.
• W1991336487 hasLocation W19913364871 @default.
• W1991336487 hasLocation W19913364872 @default.
• W1991336487 hasLocation W19913364873 @default.
• W1991336487 hasLocation W19913364874 @default.
• W1991336487 hasLocation W19913364875 @default.
• W1991336487 hasOpenAccess W1991336487 @default.
• W1991336487 hasPrimaryLocation W19913364871 @default.
• W1991336487 hasRelatedWork W1967302854 @default.

• next